{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:02:59Z","timestamp":1788973379627,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pharma.2024.03.007","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T18:17:34Z","timestamp":1711649854000},"page":"780-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A UPLC method development and validation study of Upadacitinib and its impurities in extended \u2013 release oral tablet dosage forms"],"prefix":"10.1016","volume":"82","author":[{"given":"Rajya Lakshmi","family":"Nimmagadda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowjanya","family":"Gummadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2024.03.007_bib0005","unstructured":"Europe PMC. URL: https:\/\/europepmc.org\/article\/NBK\/nbk572088. Accessed on [March 30, 2023]"},{"key":"10.1016\/j.pharma.2024.03.007_bib0010","unstructured":"European Medicines agency. URL: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq. Accessed on [March 30, 2023]."},{"issue":"1","key":"10.1016\/j.pharma.2024.03.007_bib0015","first-page":"113","article-title":"Related substances method development and validation of Axitinib, Zanubrutinib and Upadacitinib using RP-HPLC and its degradation products were characterized by using LC-MS\/MS","volume":"13","author":"Ibrahim","year":"2023","journal-title":"Int J Pharm Investig"},{"key":"10.1016\/j.pharma.2024.03.007_bib0020","doi-asserted-by":"crossref","first-page":"123076","DOI":"10.1016\/j.jchromb.2021.123076","article-title":"Quantification of the Janus kinase 1 inhibitor Upadacitinib in human plasma by LC-MS\/MS","volume":"1188","author":"Martens-Lobenhoffer","year":"2022","journal-title":"J Chromatogr B"},{"issue":"06","key":"10.1016\/j.pharma.2024.03.007_bib0025","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.47750\/pnr.2022.13.S06.442","article-title":"Quantification of an anti-rheumatic agent: Upadacitinib in biological fluid (plasma) by LC-MS\/MS","volume":"13","author":"Venkateswara Rao","year":"2022","journal-title":"J Pharm Negat Results"},{"issue":"2","key":"10.1016\/j.pharma.2024.03.007_bib0030","first-page":"102","article-title":"Validation of LC-MS\/MS method for monitoring of Upadacitinib in rat plasma samples","volume":"13","author":"Inturi","year":"2022","journal-title":"J Pharm Negat Results"},{"key":"10.1016\/j.pharma.2024.03.007_bib0035","doi-asserted-by":"crossref","first-page":"123071","DOI":"10.1016\/j.jchromb.2021.123071","article-title":"Simultaneous measurement of Upadacitinib and Methotrexate by UPLC-MS\/MS and its pharmacokinetic application in rats","volume":"1188","author":"Li","year":"2022","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.pharma.2024.03.007_bib0040","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.2147\/DDDT.S332282","article-title":"Development of an UPLC-MS\/MS method for the quantitative analysis of Upadacitinib in beagle dog plasma and pharmacokinetics study","volume":"15","author":"Wang","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.pharma.2024.03.007_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-019-0378-y","article-title":"Development of in vitro\u2013in vivo correlation for Upadacitinib extended-release tablet formulation","volume":"21","author":"Mohamed","year":"2019","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.pharma.2024.03.007_bib0050","series-title":"Harmonized tripartite guideline: Impurities in new drug substances Q3A (R2)","year":"2006"},{"key":"10.1016\/j.pharma.2024.03.007_bib0055","series-title":"Harmonized tripartite guideline: Impurities in new drug products Q3B (R2)","year":"2006"},{"key":"10.1016\/j.pharma.2024.03.007_bib0060","series-title":"Harmonized tripartite guideline: Validation of analytical procedures: Text and methodology ICH Q2 (R1)","year":"2005"},{"key":"10.1016\/j.pharma.2024.03.007_bib0065","series-title":"Harmonized tripartite guideline: Stability testing of new drugs and products Q1A (R2)","year":"2003"},{"key":"10.1016\/j.pharma.2024.03.007_bib0070","series-title":"Harmonized tripartite guideline: Photostability testing of new drug substances and drug products Q1B (R2)","year":"1996"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:14:05Z","timestamp":1724951645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450924000427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0003450924000427"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.03.007","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A UPLC method development and validation study of Upadacitinib and its impurities in extended \u2013 release oral tablet dosage forms","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}